China Isotope & Radiation Corporation (1763.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
China Isotope & Radiation Corporation
Sector
Healthcare
Industry
Medical - Devices
Employees
3367
First IPO Date
July 06, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Yafei Xiao | Chairman | 589,181 | 1976 |
| Xiaoyu Ma | Executive Director | 1.11M | 1981 |
| Yingying Huo | Executive Director | 1.11M | 1983 |
| Jin Du | Chief Engineer | 1.28M | 1966 |
| Junqi Zhang | GM & Executive Director | 1.56M | 1972 |
| Yuntao Liu | Deputy GM & Chief Engineer | 0 | 1972 |
| Cangren Wang | Chief Accountant, Joint Secretary & General Legal Counsel | 0 | 1977 |
| Sau In Kwan | Joint Secretary | 0 | N/A |
Description
China Isotope & Radiation Corporation is dedicated to the development, production, and distribution of diagnostic and therapeutic radiopharmaceuticals, as well as radioactive source products for both medical and industrial applications throughout China. The company's operations are divided into five principal areas. Its Pharmaceuticals division focuses on creating and marketing imaging diagnostic and therapeutic radiopharmaceuticals, UBT kits and analyzers, and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment furnishes medical and industrial radioactive sources, along with associated technical support services. The Irradiation segment offers sterilization services for products such as medical devices, food, traditional Chinese medicine, and cosmetics, in addition to providing engineering, procurement, and construction (EPC) services for gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment handles the sale of radiation therapy equipment and its corresponding maintenance. Finally, the Independent Clinical Medical and Laboratory Services, and Other Business segment delivers independent clinical laboratory services to hospitals and other medical institutions, covering a range of conditions including hepatitis, endocrine disorders, bone metabolism issues, cardiovascular diseases, and diabetes. Founded in 1983, the company's main office is located in Beijing, China, and it operates as a subsidiary of China National Nuclear Corporation.